Gene variability and degree of expression of vaccine candidate factor H binding protein in clinical isolates of Neisseria meningitidis

APMIS

Volumn 121, Issue 1, 2013, Pages 56-63

  Kelly, Anne ^a   Jacobsson, Susanne ^b   Hussain, Shahida ^a   Olcén, Per ^b   Mölling, Paula ^b  

^a ÖREBRO UNIVERSITY   (Sweden)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Factor H binding protein; Fluorescence activated cell sorting; Neisseria meningitidis; Sequencing; Vaccine; Western blot

Indexed keywords

BACTERIAL VACCINE; FACTOR H BINDING PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; FLUORESCENCE ACTIVATED CELL SORTING; GENE; GENE EXPRESSION; GENE FREQUENCY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MENINGOCOCCOSIS; MORTALITY; NEISSERIA MENINGITIDIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SWEDEN; WESTERN BLOTTING;

ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL VACCINES; BLOTTING, WESTERN; DNA, BACTERIAL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, BACTERIAL; GENETIC VARIATION; HUMANS; MENINGOCOCCAL INFECTIONS; NEISSERIA MENINGITIDIS, SEROGROUP B; PHYLOGENY; POLYMERASE CHAIN REACTION;

EID: 84871647402     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2012.02934.x     Document Type: Article

References (22)

1. Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev 2007;31:3-14.
2. Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983;2:355-7.
3. Wyle FA, Artenstein MS, Brandt BL, Tramont EC, Kasper DL, Altieri PL, et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis 1972;126:514-21.
4. Masignani V, Comanducci M, Giuliani MM, Bambini S, Adu-Bobie J, Arico B, et al. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med 2003;197:789-99.
5. Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, Knauf M, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004;72:2088-100.
6. Harris SL, Zhu D, Murphy E, McNeil LK, Wang X, Mayer LW, et al. Preclinical evidence for the potential of a bivalent fHBP vaccine to prevent Neisseria meningitidis Serogroup C Disease. Hum Vaccin 2011;7(Suppl):68-74.
7. Murphy E, Andrew L, Lee KL, Dilts DA, Nunez L, Fink PS, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis 2009;200:379-89.
8. Lucidarme J, Tan L, Exley RM, Findlow J, Borrow R, Tang CM. Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein. Clin Vaccine Immunol 2011;18:1002-14.
9. Koeberling O, Delany I, Granoff DM. A critical threshold of meningococcal factor H binding protein expression is required for increased breadth of protective antibodies elicited by native outer membrane vesicle vaccines. Clin Vaccine Immunol 2011;18:736-42.
10. Jacobsson S, Hedberg ST, Molling P, Unemo M, Comanducci M, Rappuoli R, et al. Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease. Vaccine 2009;27:1579-84.
11. Jacobsson S, Olcen P, Lofdahl M, Fredlund H, Molling P. Characteristics of Neisseria meningitidis isolates causing fatal disease. Scand J Infect Dis 2008;40:734-44.
12. Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 1987;4:406-25.
13. Van de Peer Y, De Wachter R. TREECON for Windows: a software package for the construction and drawing of evolutionary trees for the Microsoft Windows environment. Comput Appl Biosci 1994;10:569-70.
14. Beernink PT, Granoff DM. The modular architecture of meningococcal factor H-binding protein. Microbiology 2009;155:2873-83.
15. Brehony C, Wilson DJ, Maiden MC. Variation of the factor H-binding protein of Neisseria meningitidis. Microbiology 2009;155:4155-69.
16. Brunelli B, Del Tordello E, Palumbo E, Biolchi A, Bambini S, Comanducci M, et al. Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1. Vaccine 2011;29:1072-81.
17. Cantini F, Veggi D, Dragonetti S, Savino S, Scarselli M, Romagnoli G, et al. Solution structure of the factor H-binding protein, a survival factor and protective antigen of Neisseria meningitidis. J Biol Chem 2009;284:9022-6.
18. Dunphy KY, Beernink PT, Brogioni B, Granoff DM. Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood. Infect Immun 2011;79:353-9.
19. McNeil LK, Murphy E, Zhao XJ, Guttmann S, Harris SL, Scott AA, et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine 2009;27:3417-21.
20. Seib KL, Brunelli B, Brogioni B, Palumbo E, Bambini S, Muzzi A, et al. Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies. Infect Immun 2011;79:970-81.
21. Wang X, Cohn A, Comanducci M, Andrew L, Zhao X, MacNeil JR, et al. Prevalence and genetic diversity of candidate vaccine antigens among invasive Neisseria meningitidis isolates in the United States. Vaccine 2011;29:4739-44.
22. Madico G, Welsch JA, Lewis LA, McNaughton A, Perlman DH, Costello CE, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol 2006;177:501-10.